Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
- PMID: 20497143
- DOI: 10.1111/j.1365-2036.2010.04370.x
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
Abstract
Background: Most studies evaluating chronic hepatitis C virus (HCV) natural history have taken the development of cirrhosis as an end-point.
Aim: To perform a systematic review of the literature to establish the outcome of compensated HCV cirrhosis.
Methods: A systematic literature review was performed. Only data regarding HCV mono-infected patients were included. Weighted mean annual percentage rates for death/transplantation, decompensation of cirrhosis and development of HCC were calculated.
Results: Thirteen papers were included. Despite some heterogeneity, we extracted data relating to 2386 patients. In compensated HCV cirrhosis, the estimated annual rate of death/transplantation is 4.58%, that of decompensation is 6.37% per and that of HCC, 3.36%. When compared with studies of untreated patients, studies that included treated patients reported significantly lower mean annual percentage rates of HCC (2.52% vs. 4.79%, P = 0.02), but not decompensation (5.34% vs. 7.88%, P = 0.026) and death/transplantation (3.79% vs. 4.62%, P = 0.25).
Conclusions: These rates highlight the need for continued vigilance for the occurrence of HCC, while confirming the relatively slow progress of compensated HCV cirrhosis. Heterogeneity in reporting means that these data may underestimate the rate of disease progression, particularly HCC development. It will be important to ensure clearer distinction between treatment responses in future studies.
Similar articles
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340. Health Technol Assess. 2007. PMID: 17767898
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2. Cochrane Database Syst Rev. 2016. PMID: 26934429 Free PMC article.
-
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?Am J Gastroenterol. 2003 Nov;98(11):2535-42. doi: 10.1111/j.1572-0241.2003.07678.x. Am J Gastroenterol. 2003. PMID: 14638360
Cited by
-
Natural history of HCV infection.Hepatol Int. 2012 Oct;6(4):684-95. doi: 10.1007/s12072-012-9355-6. Epub 2012 Mar 9. Hepatol Int. 2012. PMID: 26201520
-
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.EBioMedicine. 2016 Oct;12:55-67. doi: 10.1016/j.ebiom.2016.07.013. Epub 2016 Jul 14. EBioMedicine. 2016. PMID: 27688096 Free PMC article.
-
Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.Hepat Oncol. 2015 Jul;2(3):291-302. doi: 10.2217/hep.15.16. Epub 2015 Jul 27. Hepat Oncol. 2015. PMID: 30191009 Free PMC article. Review.
-
Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Neuropsychiatr Dis Treat. 2011;7:275-92. doi: 10.2147/NDT.S13917. Epub 2011 May 15. Neuropsychiatr Dis Treat. 2011. PMID: 21654873 Free PMC article.
-
Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma.Oncotarget. 2014 Sep 30;5(18):8429-41. doi: 10.18632/oncotarget.2316. Oncotarget. 2014. PMID: 25238261 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical